Microbiology Spectrum · 6 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study used a mouse model of Clostridium difficile infection (CDI) to investigate butyrate's protective effects. The central result is that butyrate treatment reduced CDI severity by enhancing intestinal barrier function, reducing inflammation, and restoring bile acid metabolism through regulation of bile salt hydrolase (BSH) bacteria and activation of the farnesoid X receptor (FXR).
The study investigated butyrate's role in treating Clostridium difficile infection (CDI) using a classic murine CDI model. The authors found that butyrate treatment significantly inhibited CDI development by enhancing intestinal barrier protection, exerting anti-inflammatory effects, and regulating bile acid metabolism. Specifically, butyrate promoted the production of secondary bile acids by increasing bile salt hydrolase (BSH)-producing flora and activated the farnesoid X receptor (FXR). The protective effects of butyrate were reduced when mice were co-treated with inhibitors of BSH or FXR. The findings suggest butyrate may be a potential novel therapeutic approach for CDI, but this requires validation in human studies.
